/
OSTX
$2.24+$0.36 (+19.15%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$83.7M
45M shares
52-week range
$1.15 – $2.57
77% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Borrow rate
2.74%
Moderate
Price (6 mo)
Loading chart…
Change$-0.27
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $4.3K | $1.2M | $805 | $4.2K | $2.8K | $363.1K |
| Gross profit | −$4.3K | −$1.2M | −$805 | −$4.2K | −$2.8K | −$363.1K |
| Gross margin | — | — | — | — | — | — |
| R&D | $602 | $2.2M | $3.3M | $3.2M | $2.8M | $16.36B |
| Operating income | −$5.6K | −$4.8M | −$4.4M | −$4.3M | −$6.8M | −$28.7M |
| EBITDA | $61.4K | −$4.8M | −$4.4M | −$4.3M | −$6.8M | −$28.4M |
| Net income | −$6.0K | −$7.4M | −$6.3M | −$7.8M | −$8.9M | −$28.8M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.00 | -0.33 | -0.28 | -0.39 | -0.52 | -0.98 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-0.70 | $-0.70–$-0.69 | 1 |
| 2027 | $33M | $-0.15 | $-0.15–$-0.15 | 2 |
| 2028 | $59M | $-0.05 | $-0.89–$0.79 | 2 |
| 2029 | $94M | $0.18 | $0.18–$0.18 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
OS Therapies Incorporated
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
www.ostherapies.com- Employees
- 5
- IPO / List date
- Aug 1, 2024
- HQ
- ROCKVILLE, MD
Held by traders on TradeandTell
No one on the platform currently holds OSTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in OSTX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OSTX yet.
